drugset / Trial / NCT05446168
Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Small exploratory open-label pilot study to assess the short-chain fatty acid (SCFA) prodrug tributyrin as a potential therapy for persons with Parkinson disease
Timeline
- Start
- 2022-07-01
- Primary completion
- 2023-09-26
- Completion
- 2023-09-26
Outcome
Mixed primary results
Stopped (Business): “Withdrawal of funding”
registry analysis (other test); Parkinson's Disease Tributyrin Intervention; p = 0.005; Mean Difference (Net) -0.08 (95% CI -0.12 to -0.03); t-test, 2 sided NCT05446168 ↗
registry Lower radiotracer binding is interpreted to reflect higher levels of (non-tracer) butyrate in the brain NCT05446168 ↗
registry analysis (other test); Parkinson's Disease Tributyrin Intervention; p = 0.27; Mean Difference (Net) 4.33 (95% CI -3.81 to 12.47); t-test, 2 sided NCT05446168 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tributyrin | Other / unclassified | 500 mg | — |